Inhibikase Therapeutics (NASDAQ:IKT) & CorMedix (NASDAQ:CRMD) Head-To-Head Analysis

Inhibikase Therapeutics (NASDAQ:IKT) and CorMedix (NASDAQ:CRMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Profitability

This table compares Inhibikase Therapeutics and CorMedix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
CorMedix	40.49%	40.52%	20.61%

Earnings & Valuation

This table compares Inhibikase Therapeutics and CorMedix”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260,000.00	885.54	-$48.26 million	($0.43)	-3.84
CorMedix	$311.71 million	1.82	$163.05 million	$2.14	3.39

CorMedix has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Inhibikase Therapeutics and CorMedix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1	2	4	3	2.90
CorMedix	0	2	7	0	2.78

Inhibikase Therapeutics presently has a consensus target price of $4.75, indicating a potential upside of 187.88%. CorMedix has a consensus target price of $15.00, indicating a potential upside of 106.61%. Given Inhibikase Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Inhibikase Therapeutics is more favorable than CorMedix.

Risk & Volatility

Inhibikase Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Summary

CorMedix beats Inhibikase Therapeutics on 10 of the 15 factors compared between the two stocks.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

About CorMedix

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.